Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dry Eye Syndrome (DES) Clear all

Conditions: Ocular Surface Disease, Dry Eye Syndrome (DES)
Interventions: (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%; Drug
Lead sponsor: Pittsburgh Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sewickley, Pennsylvania

Conditions: Dry Eye Syndrome (DES), Meibomian Gland Dysfunction (Disorder)
Interventions: Manual expression of meibomian glands after thermal eyelid therapy; Device
Lead sponsor: Cleveland Eye Clinic; Other
Eligibility: 50 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Largo, Florida • Brecksville, Ohio

Conditions: Dry Eye Syndrome (DES), Dry Eye Disease (DED)
Interventions: Miebo four times per day; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Bozeman, Montana • Omaha, Nebraska • Fargo, North Dakota + 1 more

Conditions: Keratoconjunctivitis Sicca
Interventions: Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye
Interventions: ECF843, ECF843 vehicle; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 52
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more

Conditions: Dry Eye Syndrome
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more

Conditions: Dry Eye Syndrome
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 10
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 7 more

Conditions: Dry Eye Syndromes, Dry Eye
Interventions: RGN-259, Placebo; Drug
Lead sponsor: ReGenTree, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 20
States / cities: Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 16 more

Search by objective public record fields.

This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery

A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3